University of Michigan

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Michigan</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Ann Arbor, Michigan, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public research university</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1817</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://umich.edu/" target="_blank">University of Michigan official site</a></td>
</tr>
<tr>
<td class="label">Neurodegeneration Focus</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Dementia, Neuroscience</td>
</tr>
<tr>
<td class="label">Major Units</td>
<td>Michigan Neuroscience Institute, Department of Neurology, School of Public Health</td>
</tr>
</table>

University of Michigan

The University of Michigan, founded in 1817 in Ann Arbor, is one of the United States' leading public research universities with over $1.5 billion in annual research funding. Through Michigan Medicine and the Michigan Neuroscience Institute, the university has established comprehensive programs in neurodegenerative disease research and clinical care, making it a major center for Alzheimer's disease, Parkinson's disease, ALS, and other neurological disorders in the Midwest[@university][@michigan].

History and Institutional Evolution

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Michigan</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Ann Arbor, Michigan, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public research university</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1817</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://umich.edu/" target="_blank">University of Michigan official site</a></td>
</tr>
<tr>
<td class="label">Neurodegeneration Focus</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Dementia, Neuroscience</td>
</tr>
<tr>
<td class="label">Major Units</td>
<td>Michigan Neuroscience Institute, Department of Neurology, School of Public Health</td>
</tr>
</table>

University of Michigan

The University of Michigan, founded in 1817 in Ann Arbor, is one of the United States' leading public research universities with over $1.5 billion in annual research funding. Through Michigan Medicine and the Michigan Neuroscience Institute, the university has established comprehensive programs in neurodegenerative disease research and clinical care, making it a major center for Alzheimer's disease, Parkinson's disease, ALS, and other neurological disorders in the Midwest[@university][@michigan].

History and Institutional Evolution

The University of Michigan has been a leader in medical research since its founding. The Medical School was established in 1850, and the Neurology department has grown into one of the nation's premier programs for neurodegenerative disease research and clinical care. Over the past two decades, the institution has significantly expanded its neuroscience infrastructure, establishing the Michigan Neuroscience Institute in 2015 to coordinate interdisciplinary research across basic, translational, and clinical neuroscience["@michigana"].

The Michigan Alzheimer's Disease Research Center (MADRC), established in 1992, has been continuously funded by the NIH as one of 33 Alzheimer's Disease Research Centers nationwide. The center has contributed extensively to understanding early detection biomarkers, disease progression mechanisms, and therapeutic interventions for Alzheimer's disease["@madrc"].

Academic Medical Center

Michigan Medicine

Michigan Medicine serves as the academic medical center for the University of Michigan, comprising:

• University Hospital: A 1,000-bed tertiary and quaternary care facility ranked among the nation's best
• C.S. Mott Children's Hospital: Specialized pediatric care
• Frankel Cardiovascular Center: Leading cardiovascular research and treatment
• W.A. ForeSCIence Cancer Center: Comprehensive oncology program
• Multiple specialty clinics: Including the Memory Disorders Clinic, Movement Disorders Clinic, and ALS Center

Michigan Neuroscience Institute

The Michigan Neuroscience Institute (MNI) coordinates neuroscience research across the university, bringing together researchers from multiple departments to tackle complex neurological diseases. The institute supports:

• Basic science research on neural function and disease mechanisms
• Translation research developing new therapeutics
• Clinical trials for neurological diseases
• Training the next generation of neuroscientists
• Multidisciplinary collaboration with engineering, public health, and computational sciences

Key Research Areas

Alzheimer's Disease Research

Michigan researchers investigate multiple aspects of Alzheimer's disease pathogenesis and treatment:

Amyloid and Tau Pathology Mechanisms: Researchers study the molecular pathways underlying amyloid-beta aggregation and tau hyperphosphorylation, including the role of presenilin mutations in familial Alzheimer's disease. Recent work has characterized how different amyloid-beta species contribute to synaptic toxicity and cognitive decline[@chen2024].

Biomarker Development for Early Detection: The MADRC has pioneered cerebrospinal fluid and blood-based biomarker studies, identifying novel combinations of tau, amyloid, and neurofilament light chain measurements that can detect Alzheimer's pathology decades before clinical symptoms appear[@starr2024][@kaur2024].

Neuroinflammation in AD Progression: University of Michigan scientists have conducted landmark studies on microglial activation and neuroinflammation in Alzheimer's disease, demonstrating how chronic neuroinflammatory responses contribute to disease progression and identifying potential anti-inflammatory therapeutic targets[@chen2023].

Genetic Risk Factors in Diverse Populations: Researchers are investigating genetic risk factors in diverse populations, addressing the historical underrepresentation of non-European ancestry groups in Alzheimer's disease genetics. This work has identified novel risk variants and provided insights into health disparities in disease prevalence and progression[@forrest2024].

Parkinson's Disease and Movement Disorders

The Udall Center for Parkinson's Disease Research at the University of Michigan leads innovative research programs:

LRRK2 Biology in PD Pathogenesis: Michigan researchers have conducted extensive studies on LRRK2 mutations, one of the most common genetic causes of familial Parkinson's disease. Work has characterized how LRRK2 kinase hyperactivity leads to dopaminergic neuron degeneration and has identified potential LRRK2 inhibitors for disease modification[@friedman2024].

Alpha-Synuclein Biology and Aggregation: Researchers study the mechanisms underlying alpha-synuclein aggregation and propagation, including the role of specific protein modifications in promoting oligomer formation and cell-to-cell transmission of pathological species[@morton2023].

Deep Brain Stimulation Outcomes: Michigan Medicine's Movement Disorders program has pioneered advanced deep brain stimulation techniques for Parkinson's disease, including programming optimization and targeting strategies. Research has demonstrated improved outcomes with contemporary DBS approaches compared to standard medication therapy[@singh2023].

GBA Gene Mutations and PD Risk: Studies on glucocerebrosidase (GBA) gene variants have established these as significant risk factors for Parkinson's disease, with researchers investigating how GBA mutations lead to alpha-synuclein accumulation and exploring gene therapy approaches[@boken2023].

Non-Motor Symptoms: Research programs address cognitive decline, depression, and autonomic dysfunction in Parkinson's disease, recognizing that these symptoms significantly impact patient quality of life and often precede motor symptoms[@nguyen2024].

Levodopa-Induced Dyskinesias: Studies on the mechanisms underlying dyskinesias have identified targets for novel pharmacological interventions and refined understanding of basal ganglia circuitry dysfunction[@johnson2023].

ALS Research

The ALS Center of Excellence at the University of Michigan conducts comprehensive research on amyotrophic lateral sclerosis:

Genetic Screening: The center offers comprehensive genetic testing for ALS patients, including testing for known genes (C9orf72, SOD1, TARDBP, FUS) and identification of novel variants through whole exome sequencing.

Novel Therapeutic Approaches: Researchers have investigated multiple disease-modifying strategies, including antisense oligonucleotide therapies, small molecule inhibitors, and neuroprotective agents. Recent clinical trials have focused on targeting specific genetic mutations in familial ALS[@paulsen2024].

Stem Cell Models: Michigan scientists have developed induced pluripotent stem cell (iPSC) models from ALS patients, enabling study of disease mechanisms in patient-derived motor neurons and screening of potential therapeutic compounds.

Biomarker Discovery: Research programs aim to identify fluid and neuroimaging biomarkers that can track disease progression and serve as outcome measures for clinical trials.

Center for Cognitive Disorders

The Center for Cognitive Disorders provides comprehensive clinical services and conducts research on:

• Comprehensive memory evaluation and diagnosis
• Clinical trials for Alzheimer's disease therapeutics
• Neuroimaging research using advanced MRI and PET techniques
• Patient and family support services and caregiver education

Notable Research Programs

Michigan Alzheimer's Disease Research Center (MADRC)

The MADRC is one of 33 NIH-funded Alzheimer's Disease Research Centers, with the following research themes:

• Clinical Research: Early detection studies using cognitive assessments and biomarkers
• Brain Tissue Bank: Postmortem brain tissue for research on disease mechanisms
• Training Program: Fellowship training for dementia specialists
• Community Outreach: Education programs for patients, families, and healthcare providers
• Biomarker Core: Development and validation of CSF, blood, and imaging biomarkers

Udall Center for Parkinson's Disease Research

The Udall Center focuses on understanding the pathogenesis of Parkinson's disease and developing novel therapeutic approaches:

• LRRK2 biology in PD pathogenesis
• Alpha-synuclein propagation mechanisms
• Novel therapeutic target identification
• Translation of basic findings to clinical applications
• Training the next generation of PD researchers

ALS Center of Excellence

The ALS Center provides multidisciplinary care and conducts innovative research:

• Multidisciplinary clinical care including pulmonology, nutrition, and rehabilitation
• Clinical trials for new therapies
• Basic research on motor neuron degeneration
• Stem cell and animal model development
• Biomarker discovery for disease monitoring

Notable Researchers

Dr. Roger L. Albin

Dr. Albin's research focuses on basal ganglia function and degeneration in Parkinson's disease and related disorders. His work has advanced understanding of circuitry changes underlying motor symptoms and has informed deep brain stimulation targeting strategies. His laboratory has published extensively on the neurobiology of parkinsonian syndromes and has contributed to the development of novel therapeutic approaches[@albin2023].

Dr. Henry Paulsen

Dr. Paulsen directs the ALS Center and conducts research on novel therapeutic approaches for motor neuron disease. His work focuses on developing disease-modifying therapies for ALS, including studies on genetic forms of the disease and translation of basic science findings to clinical applications[@paulsen2024].

Dr. Bruno Giordani

Dr. Giordani leads clinical research on Alzheimer's disease diagnosis and treatment outcomes. His work includes development of cognitive assessment tools, neuroimaging biomarkers, and clinical trial outcome measures. He has served as principal investigator on numerous Alzheimer's disease clinical trials[@giordani2024].

Training Programs

The University of Michigan offers comprehensive training in neurodegenerative disease research:

• Neurology Residency Program: Four-year residency training with emphasis on movement disorders and cognitive neurology
• Movement Disorders Fellowship: One-year clinical and research fellowship
• Cognitive Neurology Fellowship: Training in diagnosis and management of dementia
• ALS Fellowship: Specialized training in ALS care and research
• PhD Programs in Neuroscience: Graduate training in cellular, molecular, and systems neuroscience
• Postdoctoral Research Training: Postdoctoral positions in all neurodegeneration research areas

Clinical Trials

Michigan Medicine actively recruits patients for neurodegenerative disease clinical trials:

| Trial Type | Conditions | Status |
|------------|------------|--------|
| Amyloid-targeting antibodies | Alzheimer's disease | Recruiting/Active |
| Tau aggregation inhibitors | Alzheimer's disease | Various phases |
| LRRK2 inhibitors | Parkinson's disease | Phase 2/3 |
| Alpha-synuclein modulators | Parkinson's disease | Phase 2 |
| Neuroprotective agents | ALS, Parkinson's disease | Phase 2 |
| Gene therapy approaches | ALS, Parkinson's disease | Phase 1/2 |

Community Impact

The university's neuroscience research has significant regional impact:

• Serving Michigan's diverse population through clinical care and research participation
• Providing access to cutting-edge clinical trials for patients in the Midwest
• Community education programs on brain health and disease prevention
• Caregiver support programs and resources for families affected by neurodegenerative diseases
• Training healthcare providers across the region in dementia care

Research Infrastructure

Core Facilities

The University of Michigan provides state-of-the-art research infrastructure:

• Human Brain Tissue Bank: Postmortem brain tissue for neurodegeneration research
• Neuroimaging Core: 3T and 7T MRI, PET imaging capabilities
• Biomarker Analysis Core: CSF and blood biomarker measurement
• Stem Cell Core: iPSC generation and differentiation
• Behavioral Neuroscience Core: Cognitive testing and animal behavior facilities
• Bioinformatics Core: Computational resources for large-scale data analysis

Collaborative Networks

The university maintains extensive collaborations:

• NIH Alzheimer's Disease Research Centers program
• Parkinson's Progression Markers Initiative (PPMI)
• ALS Clinical Research Network
• International consortia for dementia research
• Industry partnerships for clinical trials

Future Directions

The University of Michigan continues to expand its neurodegenerative disease research programs:

• Precision Medicine: Development of individualized treatment approaches based on genetic and biomarker profiles
• Early Intervention: Focus on prevention and early intervention in at-risk populations
• Novel Therapeutics: Development of disease-modifying therapies targeting underlying pathological mechanisms
• Digital Health: Implementation of remote monitoring and digital biomarkers
• Diversified Research: Expanding research to include underrepresented populations

See Also

• [Institutions](/institutions) - All institution pages
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Alzheimer's disease mechanisms
• [Parkinson's Disease](/diseases/parkinsons-disease) - Parkinson's disease mechanisms
• [LRRK2](/genes/lrrk2) - Leucine-rich repeat kinase 2
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Alpha-synuclein protein
• [Tau](/proteins/tau) - Tau protein in neurodegeneration
• [GBA](/genes/gba) - Glucocerebrosidase gene

External Links

• [University of Michigan](https://umich.edu/)
• [Michigan Medicine Neurology](https://med.umich.edu/neurology/)
• [Michigan Neuroscience Institute](https://medicine.umich.edu/department/neuroscience)
• [Michigan Alzheimer's Disease Research Center](https://alzheimers.med.umich.edu/)

References